Inhaled nitric oxide in cardiology

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1947-1956

  Hayward, C S ^a   Macdonald, P S ^a   Keogh, A M ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cardiac surgery; Heart failure; Nitric oxide; Pulmonary hypertension

Indexed keywords

ACETYLCHOLINE; ARGININE; DIPYRIDAMOLE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; NITRIC OXIDE; NITRIC OXIDE DONOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SUBSTANCE P; TEPROSTINOL; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; ZAPRINAST;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOLOGY; CHRONIC DISEASE; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DRUG HALF LIFE; DRUG MECHANISM; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE FUNCTION; HUMAN; NONHUMAN; POSTOPERATIVE CARE; PULMONARY HYPERTENSION; REVIEW; VALVULAR HEART DISEASE; VASODILATATION;

ADMINISTRATION, INHALATION; ANIMALS; CARDIAC SURGICAL PROCEDURES; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; INTRAOPERATIVE COMPLICATIONS; NITRIC OXIDE; POSTOPERATIVE CARE; VASODILATOR AGENTS;

EID: 0035159969     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1947     Document Type: Review

References (129)

1. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
2. Nitric oxide: Physiology, pathophysiology and pharmacology
3. Inhaled nitric oxide: Its effects on pulmonary circulation and airway smooth muscle cells
4. Nonenzymatic nitric oxide production in humans
5. Pulmonary response of normal human subjects to inhaled vasodilator substances
6. Selective pulmonary vasodilation by inhaled nitric oxide is due to haemoglobin inactivation
7. Haemoglobin inhibits endothelium dependent relaxation to acetylcholine in human coronary arteries in vivo
8. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates
9. S-Nitrosylation of proteins with nitric oxide: Synthesis and characterisation of biologically active compounds
10. Formation of nanomolar concentrations of S-nitroso-albumin in human plasma by nitric oxide
11. Scavenging effects of haemoglobin and related heme containing compounds on nitric oxide, reactive oxidants and carcinogenic volatile nitrosocompounds of cigarette smoke. A new method for protection against constituents
12. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study
13. Biotransformation of nitric oxide
14. Conversion of inhaled nitric oxide to nitrate in man
15. Gas-phase oxidation of nitric oxide: Chemical kinetics and rate constant
16. Formation of nitrogen dioxide from nitric oxide and their measurement in clinically relevant circumstances
17. Nitrogen dioxide formation during inhaled nitric oxide therapy
18. UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS
19. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension
20. Factors influencing indoor concentrations of nitric oxide in a Parisian intensive care unit
21. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn
22. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn
23. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
24. Inhaled nitric oxide in cardiac failure: Vascular versus ventricular effects
25. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation
26. Inhaled nitric oxide in acute respiratory failure: Dose-response curves
27. The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome
28. Inhaled nitric oxide in cardiac failure: Vascular versus ventricular effects
29. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction
30. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension
31. Nitric oxide synthases and cardiovascular signalling
32. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium
33. Nitric oxide attenuates cardiac myocyte contraction
34. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins
35. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
36. Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction
37. Myocardial contractile response to nitric oxide and cGMP
38. Inotropic effects of glyceryl trinitrate and spontaneous NO donors in the dog heart
39. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin
40. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
41. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
42. Nitric oxide inhalation transiently elevates pulmonary levels of cGMP, iNOS mRNA, and TNF-alpha
43. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome
44. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide
45. Rebound pulmonary hypertension after inhalation of nitric oxide
46. Life-threatening effects of discontinuing inhaled nitric oxide in children
47. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide
48. Case 4-1993. Inhaled nitric oxide for right ventricular failure after heart transplantation
49. Altered vasoreactivity in lungs isolated from rats exposed to nitric oxide gas
50. Negative feedback regulation of endothelial cell function by nitric oxide
51. Chronic inhaled nitric oxide: Effects on pulmonary vascular endothelial function and pathology in rats
52. Regulation of the endogenous NO pathway by prolonged inhaled NO in rats
53. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: A role for superoxide
54. Recovery from withdrawal of inhaled nitric oxide and kinetics of nitric oxide-induced inhibition of nitric oxide synthase activity in vitro
55. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity
56. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease
57. Inhaled nitric oxide: Effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension
58. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
59. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
60. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
61. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
62. The effect of inhaled nitric oxide on 6-minute walk distance in patients with pulmonary hypertension
63. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension
64. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension
65. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests
66. Inhaled nitric oxide and exercise capacity in congestive heart failure
67. Beneficial effects of inhaled nitric oxide in hypoxaemic patients after coronary artery bypass surgery
68. Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure. A randomized, controlled trial
69. Inhaled nitric oxide in patients with severe heart failure: Changes in lung perfusion and ventilation detected using scintigraphy
70. Cardiac surgery and inhaled nitric oxide: Indication and follow-up (2-4 years)
71. Beneficial effects of inhaled nitric oxide in hypoxaemic patients after coronary artery bypass surgery
72. Nitric oxide gives maximal response after coronary artery bypass surgery
73. Effects of inhaled nitric oxide on respiratory system mechanics, hemodynamics, and gas exchange after cardiac surgery
74. Release of vasoactive substances during cardiopulmonary bypass
75. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery
76. Inhaled nitric oxide reduces pulmonary vascular resistance more than prostaglandin E(1) during heart transplantation
77. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass
78. Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury
79. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery
80. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension
81. Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients
82. Inhaled nitric oxide in patients with normal and increased pulmonary vascular resistance after cardiac surgery
83. Variable response to inhaled nitric oxide after cardiac surgery
84. Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension
85. Use of inhaled nitric oxide to reduce pulmonary hypertension after heart transplantation
86. Low doses of inhaled nitric oxide in heart transplant recipients
87. Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation
88. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside
89. Very-low-dose inhaled nitric oxide: A selective pulmonary vasodilator after operations for congenital heart disease
90. Effects of inhaled nitric oxide on postoperative pulmonary circulation in patients with congenital heart disease
91. Inhaled nitric oxide in congenital heart disease
92. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects
93. Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease
94. Inhaled nitric oxide differentiates pulmonary vasospasm from vascular obstruction after surgery for congenital heart disease
95. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation
96. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure
97. A theoretic analysis of the effect of pulmonary vasodilation on pulmonary venous pressure: Implications for inhaled nitric oxide therapy
98. Left ventricular chamber function during inhaled nitric oxide in patients with dilated cardiomyopathy
99. Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management
100. Nitric oxide improves transpulmonary vascular mechanics but does not change intrinsic right ventricular contractility in an acute respiratory distress syndrome model with permissive hypercapnia
101. Inhaled nitric oxide, right ventricular efficiency, and pulmonary vascular mechanics: Selective vasodilation of small pulmonary vessels during hypoxic pulmonary vasoconstriction
102. Effects of inhaled nitric oxide on right ventricular function in endotoxin shock
103. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction
104. Response to inhaled nitric oxide in patients with acute right heart syndrome
105. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device
106. Inhaled nitric oxide for the management of acute right ventricular failure in patients with a left ventricular assist system
107. Adjunctive use of inhaled nitric oxide during implantation of a left ventricular assist device
108. Hemodynamic effect of inhaled nitric oxide in dilated cardiomyopathy patients on LVAD support
109. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension
110. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance
111. Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension
112. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide
113. Selective pulmonary vasodilation induced by aerosolized zaprinast
114. Sildenafil inhibits hypoxia-induced pulmonary hypertension
115. Long-term treatment of pulmonary hypertension with aerosolised iloprost
116. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
117. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
118. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
119. Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension
120. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: Results of a double blind, randomized, placebo controlled trial
121. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium
122. Bleeding time prolongation and NO inhalation
123. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers
124. Inhaled nitric oxide does not influence bleeding time or platelet function in healthy volunteers
125. Paradoxical fate and biological action of peroxynitrite on human platelets
126. Inhaled nitric oxide increases coronary artery patency after thrombolysis
127. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds
128. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide
129. Prevention of reperfusion injury by inhaled nitric oxide in lungs harvested from non-heart-beating donors